Recombinant erythropoietin (Syntonix)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant erythropoietin (Syntonix)
Drug Alias NameEPO-FcErythropoietin-Fc
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen (Denmark) A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen (Denmark) A/S
Active IndicationsN/A
Inactive IndicationsAnemia

Other Information

ATC CodeN/A
Related LinksN/A